Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Affymetrix

Premium

CombiMatrix last week launched a microarray product for the H5N1 “Bird Flu” influenza A virus. The product targets identification of the virus and allows the tracking of mutations that can occur in its genetic makeup, the company said in a statement.


Affymetrix last week launched a new line of reagents, including two new cDNA synthesis kits, developed in collaboration with Invitrogen. The product offering is a sample preparation system for gene expression analysis. The One-Cycle cDNA Synthesis Kit contains reagents necessary for standard target labeling, using a minimum of 1 microgram of total RNA prior to the IVT labeling step.

The new Two-Cycle cDNA Synthesis Kit offers a streamlined procedure for preparing samples using small amounts of materials, such as biopsy or laser-capture-dissected samples, the company said. It contains enough reagents for performing two cycles of cDNA synthesis before IVT labeling. The two-cycle dDNA protocol takes 60 hours, the company said.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease, Study Finds

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer, Study Finds

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study says.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.